Systemic beta-Adrenoceptor Function and Ophthalmic beta-Adrenergic Blockers
| Autor: | Freddy K. Lippert, Stig Yndgaard, Preben G. Berthelsen |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Drug
Male Conjunctiva media_common.quotation_subject Adrenergic beta-Antagonists Levobunolol Mucous membrane of nose Blood Pressure Absorption (skin) Sensitivity and Specificity Heart Rate Receptors Adrenergic beta Medicine Humans media_common Aged Beta-adrenergic blocking agent business.industry Antagonist Isoproterenol Bioavailability medicine.anatomical_structure Anesthesiology and Pain Medicine Anesthesia Ophthalmic Solutions business medicine.drug |
| Zdroj: | Anesthesia & Analgesia. 82:211-213 |
| ISSN: | 0003-2999 |
| DOI: | 10.1213/00000539-199601000-00038 |
| Popis: | Approximately 80% of ophthalmic β-adrenergic blockers are systemically absorbed through conjunctival capillaries and the nasal mucosa. This absorption avoids hepatic first-pass metabolism, making the systemic bioavailability of ophthalmic drugs comparable to that of intravenously administered drugs (1). Investigations of ophthalmic β-adrenergic blockers in healthy volunteers have confirmed the systemic effects of minute amounts of drug instilled in the conjunctiva (2,3), but evaluation of β-adrenoceptor function in patients with cardiovascular pathology has not been performed. We report a case in which the hemodynamic effects of chronic use of a 0.5% ophthalmic solution of the nonselective β-adrenoceptor antagonist levobunolol (Betagan® ; Allergan, Irvine, CA) were quantified with the isoproterenol sensitivity test (4,5). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|